The Patent Finder

Terms ending in 2039

Kymab Limited

Every in-force patent on Kymab Limited's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,440,960Tigit Antibodies. Encoding Nucleic Acids and Methods of Using Said Antibodies in Vivo
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 11,680,101Anti-Opg Antibodies
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 11,919,969Bispecific Antibodies for Factor IX and Factor X
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 11,878,048Use of the Extracellular Domain of Transferrin Receptor 2 for the Diagnosis and Treatment of Primary or Secondary Sclerosing Diseases
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 10,815,308Fixaxfx Bispecific Antibody with Common Light Chain
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
US 12,723,104Improved Lambda Antibodies
In force
 · High confidence
Kymab LimitedIn forceHigh confidence
6 of 6 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited